Cardiac Screening for Hodgkin's Lymphoma Survivors
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Echo/Stress Echo for cardiac screening in Hodgkin's Lymphoma survivors?
Research shows that stress echocardiography can reveal heart abnormalities in cancer survivors who have undergone treatments like chemotherapy, which can affect the heart. This suggests that Echo/Stress Echo might be useful in detecting heart issues early in Hodgkin's Lymphoma survivors, helping to manage potential heart problems before they become serious.12345
Is cardiac screening safe for Hodgkin's Lymphoma survivors?
Cardiac screening methods like echocardiograms (heart ultrasound) and stress echocardiograms (heart ultrasound during exercise) are generally safe for humans. These tests are used to monitor heart health, especially in Hodgkin's Lymphoma survivors who may have increased risks of heart issues due to past treatments.13467
How does the Echo/Stress Echo treatment differ from other treatments for cardiac screening in Hodgkin's Lymphoma survivors?
Echo/Stress Echo is a non-invasive screening method that uses ultrasound to assess heart function and detect potential heart issues, which is particularly important for Hodgkin's Lymphoma survivors who are at increased risk of heart problems due to past radiation and chemotherapy treatments. This approach is unique because it focuses on early detection of heart issues, allowing for timely intervention and management of cardiovascular risks.13689
What is the purpose of this trial?
The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be modified either through life-style changes or medications, to uncover significant abnormal heart findings in which treatments may be needed, and to see if there is a link between cardiac health and quality of life.
Research Team
Andrea K. Ng
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for survivors of Hodgkin's disease who were treated with chest radiation at Brigham and Women's Hospital or Dana-Farber Cancer Institute, are over 15 years old, have been in remission for more than a year, and it has been five or more years since their initial treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Cardiac Screening
Participants meet with a study cardiologist and undergo cardiac risk factors screening, resting and stress echocardiogram
Follow-up
Participants are monitored for cardiac health and quality of life, with repeat screenings every 18 months to 3 years depending on time since initial treatment
Treatment Details
Interventions
- Echo/Stress Echo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Brigham and Women's Hospital
Collaborator